Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 19Myelodysplastic Syndromes 4Leukemia 3Congenital Abnormalities 3Mastocytosis, Systemic 2Recurrence 1Rectal Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Mastocytosis 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Mast-Cell 1Leukemia, Erythroblastic, Acute 1Leukemia, Eosinophilic, Acute 1Leukemia, Biphenotypic, Acute 1Leukemia, Basophilic, Acute 1Blast Crisis 1Aggression 1

Interventions

Cytarabine 34Busulfan 17Cyclophosphamide 16fludarabine phosphate 15Peripheral Blood Stem Cell Transplantation 13Filgrastim 13Etoposide 13Idarubicin 12Mitoxantrone 9Cyclosporine 9Antilymphocyte Serum 9Methotrexate 8Daunorubicin 8Whole-Body Irradiation 6Radiotherapy 6Tacrolimus 5Cord Blood Stem Cell Transplantation 5Clofarabine 5Mycophenolic Acid 4Methylprednisolone 4Melphalan 4Gemtuzumab 4Flow Cytometry 4Arsenic Trioxide 4aldesleukin 3Topotecan 3Imatinib Mesylate 3Cytogenetic Analysis 3Cyclosporins 3Bortezomib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Leukemia, Erythroblastic, Acute × midostaurin × Clear all
NCT00651261 2021-08-18

Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Alliance for Clinical Trials in Oncology

Phase 3 Unknown
717 enrolled 14 charts
LymphoidOther hematologic neoplasm

Congenital Abnormalities, Leukemia, Erythroblastic, Acute, Leukemia, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Basophilic, Acute, Leukemia, Eosinophilic, Acute, Leukemia, Myelomonocytic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡